# Lorence Kim

> Lorence Kim is a Series C investor at Ascenta Capital backing Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ascenta Capital](https://shizune.co/investors/profile/ascenta-capital)
- Location: Cambridge, United States
- Total investments: 5
- Last investment: Dec 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/lorence-kim-31006a91
- Website: https://x.com/lorencekim
- Facebook: https://www.facebook.com/lorencekim

Lorence Kim is a Series C investor at Ascenta Capital in Cambridge focused on Biotechnology and Health Care. Lorence Kim is based out of New York, New York, and is the Co-founder and Managing Partner of Ascenta Capital and the Board of Director of Triana Biomedicines. Lorence previously worked at Flare Therapeutics as a Board Member. Lorence Kim attended the Harvard University.

## Contacts

5 contacts available for Lorence Kim: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/lorence-kim?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Health Care | 3 | 60% |
| Therapeutics | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 60% |
| Series B | 2 | 40% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| Germany | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M | Series B | Dec 03, 2025 |  |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $101M | Series C | Dec 05, 2023 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $200M | Series C | Aug 09, 2023 |  |
| ADARx Pharmaceuticals | ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. | $46M | Series B | Jan 20, 2023 |  |

5 of 5 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 3 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 2 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 2 deals together

## About Ascenta Capital

VC Fund · New York, United States

Ascenta Capital is a private equity and venture capital firm.

1 contacts available at Ascenta Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Lorence Kim | Co-founder and Managing Partner | — |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Lorence Kim invest in?

Lorence Kim invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lorence Kim?

Public channels for Lorence Kim include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Lorence Kim last invest?

The most recent investment recorded for Lorence Kim closed in Dec 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co